|
|
Article: Ceragenix Pharmaceuticals Initiates EpiCeram(R) Clinical Trial; EpiCeram(R) to be Compared to Mid-Strength Steroid in Children with Moderate-to-Severe Eczema.
- Article from:
- Business Wire
- Article date:
- August 14, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DENVER -- Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, today announced that it has begun enrolling patients in a multicenter pediatric clinical study designed to assess the efficacy of EpiCeram(R) compared to Cutivate(R), a commonly prescribed mid-strength steroid, in patients with moderate-to-severe atopic dermatitis (eczema). The Company expects to report results of this trial in the fourth quarter of 2006.
The study will consist of 90 children between the ages of 6 months and 18 years of age. 45 children will receive treatment with EpiCeram and 45 will receive treatment with the steroid for a 4-week ...